An exit interview with Bristol Myers Squibb CEO; Sarepta’s Duchenne gene therapy fails to meet primary endpoint in pivotal trial

Taking stock of the drug industry, from the lab to the medicine chest

October 30, 2023 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Emilie Pickering for STAT STAT+ | An exit interview with Bristol Myers Squibb CEO Giovanni Caforio When Bristol Myers Squibb CEO Giovanni Caforio steps down, he will be replaced by Christopher Boerner, who is currently COO. By Matthew Herper Opinion: Liquid biopsy for cancer recurrence creates a new kind of patient-in-waiting When a test to predict my husband's cancer recurrence came back positive, there was only one thing we could do: wait. By Mara Buchbinder STAT+ | Cassava pulled back the curtain on its Alzheimer's study — and revealed insurmountable problems Cassava's assertion that simufilam is showing "disease-modifying activity" falls when details of its study are scrutinized. By Adam Feuerstein Ruby Wallau for STAT STAT+ | Sarepta's Duchenne gene therapy fails to meet primary endpoint in pivotal trial The results from Sarepta are likely a major disappointment for patients and doctors who have been awaiting this Duchenne treatment for years. By Jason Mast and Adam Feuerstein

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2023, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser